Pretransplant Psychiatric Evaluations - A Survey of NMDP Programs  by Steinberg, Amir et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278S270respectively, with no difference in incidence of C. difﬁcile-
associated diarrhea.
Administration of GSB was well tolerated and safe, and with
no associated fungemia. The administration of GSB in the
immediate pre-transplant period did not impact LOS, inci-
dence and severity of mucositis, or incidence and volume of
diarrhea. Complete analysis and subgroup analysis are being
performed and will be presented at the meeting.
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Background: Vaccine-preventable diseases continue to pose
a risk to HSCT recipients, thus guidelines recommend routine
vaccination after HSCT. Pediatric data is limited regarding
vaccine immunogenicity post-HSCT and may contribute to
inconsistent vaccination practices.
Objective: Prospective, observational study to determine the
immunogenicity of hepatitis B, tetanus, and pneumococcal
vaccination in children after HSCT. Secondary objective was
to evaluate correlation with T&B cell numbers.
Patients and Methods: Children receiving a HSCT from
January 2010 thru October 2012were prospectively followed.
Three doses of Hepatitis, PCV 13, and Pentacel were given per
guidelines two months apart. Pre and post vaccine-speciﬁc
antibodies and T&B cell studies were performed at 6 and 12
months post-HSCT.
Results: Compliance with current vaccine recommendations
occurred in 15 of 33 (45 %) subjects. Of the 15 subjects, 12
were evaluable receiving vaccinations and lab draws
according to the predeﬁned schedule. Patient characteristics
are described in Table 1.
Time to immunization post HSCT was a median of 197
days [180-404]. 2/12 subjects were chronic GVHD patients on
immunosuppression at the time of re-vaccination. One of
these patients did not respond to vaccination. Protective
antibody levels were found for tetanus in 83% of subjects
(median of 2.6 IU/mL [range 0.1-7]) and 69% of patients for
hepatitis. 4 evaluable subjects responded to at least 1Table 1
Patient Characteristics
Male 8 (62%)
Age at transplant 7.8 (0.6-18.9)
Transplant Type
Allogeneic 11 (85%)
Autologous 2 (15%)
Donor Source
Bone marrow 7 (54%)
Peripheral blood 3 (23%)
Umbilical cord blood 3 (23%)
Preparative Regimen
Myeloablative 10 (77%)
Serotherapy 6 (60%)
Non-myeloblative 3 (23%)
Serotherapy 2 (67%)
GVHD Prophylaxis
CNI/MTX 6 (60%)
CNI/MMF 4 (40%)pneumococcal serotype, 2 of 4 (50%) to at least 6 serotypes;
3, 4, 6B, and 19F were most immunogenic. There was no
correlation between total peripheral WBC or CD3, CD8, CD19
numbers and tetanus antibody concentrations.
Conclusions: Despite the small sample size in our cohort,
hepatitis, tetanus, and pneumococcal vaccination was
immunogenic in a majority of subjects when given 6 months
post HSCT. Pneumococcal serotypes cited to cause invasive
disease post HSCT were most immunogenic, but additional
data is needed.319
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Advances in autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) over the past 20 years may have
had an impact on the morbidity and mortality associated
with infections post-transplant. We sought to retrospectively
analyze the epidemiology and risk factors for bacterial,
fungal, viral, and parasitic infections 0-30 days post-trans-
plant in a cohort of 385 autologous and 759 allogeneic
pediatric HSCT recipients transplanted in a single institution
between1990 to 2009. Risk factors were evaluated using
logistic regression. Infections occurred in 98 (25%) autolo-
gous compared to 307 (40%) allogeneic HSCT patients. Gram-
positive bacterial infections were more prevalent than gram-
negative bacterial infections in both autologous (P ¼ .003)
and allogeneic (P < .0001) HSCT patients. Bacteremia
occurred in 31 (8%) autologous and 59 (8%) allogeneic HSCT
patients. Autologous HSCT patients with a diagnosis of
leukemia were at a higher risk for bacterial infections
compared to those with solid tumors (P ¼ .004, OR 2.80, 95%
CI 1.39-5.66). Infections due to fungal and parasitic patho-
gens in autologous HSCT patients were uncommon, and
occurred exclusively prior to 2000. Candidemiawas detected
in 26 (3%) and aspergillosis in 49 (6%) allogeneic recipients.
Herpes-Simplex virus was the most common cause of viral
infections in both autologous and allogeneic recipients.
Cytomegalovirus donor/recipient status increased risk for all
viral infections for allogeneic HSCT recipients (P ¼ .0004).
Only 3 (0.8%) deaths were attributed to infection after
autologous HSCT. All occurred prior to 2000 in patients
transplanted for acute myeloid leukemia. There were 8 (1%)
allogeneic HSCT patients who died of infections 0-30 days
post-transplant. This is the largest retrospective study on the
changing epidemiology of infections after autologous and
allogeneic HSCT in children and adolescents.320
Pretransplant Psychiatric Evaluations - A Survey of NMDP
Programs
Amir Steinberg 1, Imelda De la Vega-Diaz 2, Ina Florez 2,
Elaine Gorman 2, Carroll Hayek 3, Phyllis Kaskel 2, Sara Kim 4,
Ayelet Nelson 2, Monank Patel 2, Ginny Ross 5, Alex Rothwell 2,
Table 1
Incidence of Viral Infections
Virus n (%)
Pre-Mask
(n¼920)
Post-Mask
(n¼454) P-value
Any 10.3% (95) 3.3% (15) <0.0001
Inﬂuenza A 0.5% (5) 0.4% (2) 1.0*
*
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Background: Hematopoietic stem cell transplantation (HCT)
is a procedure that can inﬂict signiﬁcant physical and
emotional stress on patients. In particular, the emotional
stress may often lead to severe psychiatric debility, which
may affect nutrition and physical activity, and may lead to
lack of compliance with follow up andmedications for GVHD
and infection prophylaxis. At a minimum FACT requires “the
Clinical Program shall have access to certiﬁed or trained
consulting specialists and/or specialist groups from key
disciplines who are capable of assisting in the management
of patients requiring medical care, including but not limited
to Psychiatry. ” Currently our patients may sometimes be
evaluated by social work but there is no required psychiatric
referral. Referrals/consults are often made if psychiatric
issues develop. We wanted to determine what the practice is
at other transplant centers. Via QA analysis, our program
investigated whether we should institute a requirement for
a preBMT psychiatric consultation.
Methods: NMDP lists 154 programs on its website. 13
programs are non-NMDP programs. Programs were emailed
asking if the program required patients see a psychiatrist for
evaluation prior to transplant and to reply either “Yes” or
“No”. Not every program had email information provided.
Some were called.
Results: Responses were obtained for 89 of 154 total
programs and 2 of 13 non-NMDP programs. 27 NMDP
programs require a psychiatrist/ologist to see patients prior
to transplant. 7 such programs are for children. 19 NMDP
programs indicate they do not require a psychiatric evalua-
tion. 19 NMDP programs indicate patients are seen by social
work who then determines if a psychiatric evaluation is
needed (gatekeeper). 12 NMDP programs indicate that
patients are seen by social work but did not indicate whether
social work was a ”gatekeeper.” 2 NMDP programs attemp-
ted pre-BMT visits with psychiatry/ology but without
requirement. 6 programs indicate psychologic support for
patients who need intervention or insurance required. 2
programs indicate social work or psychiatry evaluate
patients. 2 of 13 programs listed as non-NMDP programs
responded. 2 NMDP programs said they were looking into
mandatory pre-BMT psychiatric evaluations.
Conclusion: A high proportion of programs require pre-BMT
psychiatric evaluations. Stress from transplant and resultant
psychiatric manifestations may lead to poor patient
compliance for follow up, failure to take medications prop-
erly, and, rarely, substance abuse. What do other programs
do and require? To increase the yield of responses we made
this a simple “yes” or “no” questionnaire yet additional
information was usually offered. Many programs declared
their interest in the results of this survey. We will follow up
with programs that did require a psychiatric evaluation
preBMT to determine if this hasmade a qualitative difference
in patient care.Inﬂuenza B 0.1% (1) 0% (0) 1.0
Parainﬂuenza 1 0.1% (1) 0% (0) 1.0*
Parainﬂuenza 2 0.3% (3) 0% (0) 1.0*
Parainﬂuenza 3 8.2% (75) 2.0% (9) <0.0001*
Adenovirus 0% (0) 0.4% (2) 1.0*
Respiratory Syncytial
Virus
1.7% (16) 0.4% (2) 0.24*
* One-sided Fisher’s Exact Test adjusted for multiple comparisons using
the Bonferroni approach321
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Respiratory viral infections (RVI) are frequent complications
of hematopoietic stem cell transplantation (HSCT). Para-
inﬂuenza virus 3 (PIV3) in particular affects patients after
HSCT, spreads nosocomially, and is associated with increased
morbidity and mortality. Given the absence of proven
effective treatments, prevention is key. Requiring all indi-
viduals with direct patient contact to wear a surgical mask is
a simple and inexpensive intervention that may reduce
droplet exposure by asymptomatic shedders and limit
nosocomial spread.
We performed a prospective study to assess the impact of
surgical masks. Between January 10, 2010-January 9, 2012
(mask period), all individuals with direct patient contact,
including caregivers, visitors, and medical staff, were
required to wear a surgical mask when within 3 feet of
a patient, regardless of suspicion of RVI. This continued until
the patient returned home after HSCT. The primary endpoint
was the incidence of RVI compared to the control period of
December 1, 2003-November 30, 2009 (pre-mask period). A
brief washout period (December 1, 2009-January 9, 2010)
allowed for implementation. Standard infection prevention
precautions were in place throughout both periods.
Secondary endpoints include clusters of RVI, deﬁned as 3 or
more infections in a 30-day period, and death from RVI. The
study was designed to detect a 40% reduction in the inci-
dence of RVI with 90% power.
During the six-year pre-mask period, 920 patients received
HSCTs. During the two-year mask period, 454 patients
received HSCTs. In the pre-mask and mask groups, median
age was 50 and 54 (P < .0001) (ranges 19 to 79 and 19 to 81).
With the exception of non-Hodgkin lymphoma (21% and
15%) and plasma cell dyscrasia (32% and 46%) (P ¼ .004),
there were no differences in disease representation. Alloge-
neic HSCT constituted 41% and 33% of transplants (P ¼ .004).
Median days at risk were 25 and 20 days (P ¼ .054).
The incidence of any RVI was 10.3% in the pre-mask period
and 3.3% in the mask period (P < .0001) (Table 1). Among
patients who had an allogeneic HSCT, the incidence was
16.9% and 6.7% (P ¼ .001); among patients who had an
autologous HSCT, the incidence was 5.7% and 1.6% (P ¼ .005).
Surgical mask usage had the most pronounced affect on
reducing the incidence of PIV3 (8.1% to 2.1%, P < .0001),
which was the most common virus (74% and 60% of infec-
tions), followed by RSV (16% and 13%). There were more
clusters in the pre-mask period (1.7/year vs. 0.5/year). In
